Trial · NCT07898384
Optimizing Care Transitions in CHD
NCT07898384, Not applicable, Not yet recruiting, The Hospital for Sick Children
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Optimizing Care Transitions in CHD. Trials, record NCT07898384. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07898384
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Optimizing Care Transitions in CHD
- NCT number
- NCT07898384
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 110 participants, estimated
- Lead sponsor
- The Hospital for Sick Children
- Conditions
- Congenital Heart Disease (CHD), Mentorship, Transition of Care, Peer Support, Peer Support and Chronic Disease, Adolescent, Young Adults, Parent
- Interventions
- Peer mentorship
- First posted
- 2026-10-27
- Last updated
- 2026-10-27
Source ClinicalTrials.gov
Registered outcomes22
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Recruitment and withdrawal rates | 12 weeks | Recruitment rates (more than 70%) and withdrawal rates (less than 15%) as calculated using data recorded in participant recruitment log. |
| Primary | Adherence | 12 weeks | Adherence with iP2P/iParent2Parent program (more than 80% rate of completion of at least five audio or video calls over 12 weeks and 100% rate of completion of all online outcome measures) as calculated using data recorded in participant program tracking log. |
| Primary | Acceptability/Level of engagement | 12 weeks | Acceptability and level of engagement of the iP2P/iParent2Parent program intervention as measured through focus groups/interviews with mentors and interviews with mentees guided by the Theoretical Framework of Acceptability. Focus groups and interviews will take approximately 45 minutes per timepoint. |
| Primary | Barriers/Enablers | 12 weeks | Barriers and enablers of the iP2P/iParent2Parent program intervention as measured through focus groups/interviews with mentors and interviews with mentees. |
| Secondary | Perceived social role satisfaction (young adult mentor outcome) | 12 weeks | Perceived social role satisfaction measured by the PROMIS Satisfaction with Social Roles and Activities. Minimum value: 0 Maximum value: 100 Higher score indicates better outcome |
| Secondary | Emotional distress (young adult mentor outcome) | 12 weeks | Emotional distress measured by the Generalized Anxiety Disorder-7 (GAD-7). Minimum value: 0 Maximum value: 21 Higher score indicates worse outcome |
| Secondary | Emotional distress (young adult mentor outcome) | 12 weeks | Emotional distress measured by the Patient Health Questionnaire-8 (PHQ-8). Minimum value: 0 Maximum value: 24 Higher score indicates worse outcome |
| Secondary | Perceived social role satisfaction (parent mentor outcome) | 12 weeks | Perceived social role satisfaction measured by the PROMIS Satisfaction with Social Roles and Activities. Minimum value: 0 Maximum value: 100 Higher score indicates better outcome |
| Secondary | Emotional distress (parent mentor outcome) | 12 weeks | Emotional distress measured by the Generalized Anxiety Disorder-7 (GAD-7). Minimum value: 0 Maximum value: 21 Higher score indicates worse outcome |
| Secondary | Emotional distress (parent mentor outcome) | 12 weeks | Emotional distress measured by the Patient Health Questionnaire-8 (PHQ-8). Minimum value: 0 Maximum value: 24 Higher score indicates worse outcome |
1 to 10 of 22Source ClinicalTrials.gov
See all 22 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07898384
GET https://conductscience.org/api/trials/v1/NCT07898384/registered?page=2